• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Kazia Therapeutics Ltd ADR (NQ: KZIA )

    0.3700 -0.0092 (-2.43%)
    Streaming Delayed Price Updated: 3:58 PM EDT, Aug 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Kazia Therapeutics Ltd ADR

    Kazia Therapeutics CEO talks $4.5 million capital raise
    Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) CEO Dr James Garner speaks with Proactive after confirming a two-tranche capital raising initiative to raise A$4.5 million through placements to... 
    Via TheNewswire.com
    Kazia Therapeutics (KZIA): Collaboration May Expand Utility to Combo Therapies
    Via ACCESSWIRE
    Kazia Therapeutics (KZIA): Q123 Cash Flows in Line with Our Estimates
    Via ACCESSWIRE
    Kazia Therapeutics (KZIA): Doubling Down on Clinical Development
    Via ACCESSWIRE
    KAZIA RECOGNISES GBM AWARENESS DAY 2022 AS IT EXPANDS CLININCAL TRIAL ACTIVITY IN EUROPE AND US
    KAZIA RECOGNISES GBM AWARENESS DAY 2022 AS IT EXPANDS CLININCAL TRIAL ACTIVITY IN EUROPE AND US Sydney, 20 July 2022 – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug... 
    Via iCrowdNewswire
    Kazia Therapeutics (KZIA): Deep Dive Into Childhood Brain Cancer
    LONDON, UK / ACCESSWIRE / May 26, 2022 / In light of the positive newsflow from Kazia's efforts in addressing adult brain cancer, management is leveraging its niche expertise and experience to address... 
    From Edison Investment Research Limited
    Via AccessWire
    Kazia TherapeuticsTrust (KZIA): Several Upcoming Catalysts
    LONDON, UK / ACCESSWIRE / March 30, 2022 / Patient recruitment in the pivotal GBM AGILE study for lead asset paxalisib remains on track, with data expected in CY23, to be followed by a potential... 
    From Edison Investment Research Limited
    Via AccessWire
    Kazia TherapeuticsTrust (KZIA): Multiple Paxalisib Data Points Expected in Q4
    LONDON, UK / ACCESSWIRE / October 14, 2021 / Kazia expects to release multiple data points from its paxalisib program in Q4 CY21. These include final data from the 30-patient Phase II trial in newly... 
    From Edison Investment Research Limited
    Via AccessWire
    Kazia Therapeutics (KZIA): New asset to target tumor lymphangiogenesis
    LONDON, UK / ACCESSWIRE / April 20, 2021 / Kazia announced that it is expanding its pipeline to include EVT801, a novel small molecule inhibitor of VEGFR3. The drug is being licensed from Evotec for... 
    From Edison Investment Research Limited
    Via AccessWire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.